U.S. Small Molecule API Market Forecast to Reach USD 103.37 Billion by 2035, Driven by HPAPI and Domestic Manufacturing

Precedence Research USA

Overview

This article presents an overview of a market research report published by Precedence Research, which projects the U.S. small molecule API market to reach USD 103.37 billion by 2035. Key growth drivers include the increasing involvement of highly potent active pharmaceutical ingredients (HPAPI) and a strong focus on domestic manufacturing initiatives. This trend is strengthening partnerships with CDMOs and promoting in-house production of critical APIs. Technological advancements, such as the integration of green chemistry and continuous manufacturing, are propelling the shift towards sustainable operations. Novartis, for example, expanded its 7th U.S. facility in April 2026 to enhance end-to-end manufacturing capabilities.

In Depth

This article provides an overview of a market research report published by Precedence Research.

Report Overview

This market research report offers a detailed analysis of the growth outlook for the U.S. small molecule Active Pharmaceutical Ingredient (API) market. The scope of the report extends to 2035, encompassing market size, growth drivers, key trends, and the competitive landscape. The report specifically focuses on the impact of increasing demand for highly potent active pharmaceutical ingredients (HPAPI), strengthening domestic manufacturing initiatives, and innovations in manufacturing technologies on market growth.

Key Findings / Results

According to the report, the U.S. small molecule API market is projected to reach a size of USD 103.37 billion by 2035. This growth is primarily driven by the following factors:

• Increased use of Highly Potent Active Pharmaceutical Ingredients (HPAPI): There is a growing development and production of highly potent drugs, particularly in oncology, which necessitates specialized handling and manufacturing capabilities.
• Focus on Domestic Manufacturing Initiatives: To enhance supply chain resilience and mitigate geopolitical risks, the U.S. government and pharmaceutical companies are accelerating investments in strengthening domestic API manufacturing capacity.
• Enhanced Partnerships with CDMOs: Pharmaceutical companies are increasingly collaborating with Contract Development and Manufacturing Organizations (CDMOs) specializing in complex API manufacturing to improve efficiency and flexibility.
• Technological Advancements: The integration of green chemistry and continuous manufacturing is transforming API production into a more sustainable and efficient process. For instance, Novartis expanded its seventh facility in the U.S. in April 2026, aiming to strengthen its end-to-end drug manufacturing capabilities and expand its market presence with modern therapeutic platforms.

About the Publishing Entity

Precedence Research is a global market research and consulting firm that provides market intelligence reports and consulting services across various industries, including healthcare, biotechnology, chemicals, and information technology. The firm supports clients’ strategic decision-making by offering in-depth market analysis, trend forecasts, and competitive intelligence. They possess deep expertise in the pharmaceutical API market, and their analyses capture key industry dynamics and future growth drivers.